Biotech News

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

Personalis (PSNL)Personalis2026-06-25 13:46 ESTConference / presentation

Abstracts span six cancer types, including new data on single-digit parts-per-million ctDNA detection FREMONT, Calif. --(BUSINESS WIRE)--May 26, 2026-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that six clinical abstracts demonstrating

Open original release

Related news

PSNLPersonalis2026-06-25 13:46 EST

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

PSNLPersonalis2026-06-25 13:46 EST

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

PSNLPersonalis2026-06-25 13:46 EST

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

PSNLPersonalis2026-06-25 13:46 EST

Personalis to Participate in Upcoming Investor Events

PSNLPersonalis2026-06-25 13:46 EST

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

PSNLPersonalis2026-06-25 13:46 EST

Personalis Reports First Quarter Results and Recent Highlights

PSNLPersonalis2026-06-25 13:46 EST

Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance

PSNLPersonalis2026-06-25 13:46 EST

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

PSNLPersonalis2026-06-25 13:46 EST

Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

PSNLPersonalis2026-06-25 13:46 EST

Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

View all latest news

Personalis

Personalis is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

PSNLPersonalis2026-06-26 13:23 EST

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

PSNLPersonalis2026-06-26 13:23 EST

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

PSNLPersonalis2026-06-26 13:23 EST

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

PSNLPersonalis2026-06-26 13:23 EST

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

PSNLPersonalis2026-06-26 13:23 EST

Personalis to Participate in Upcoming Investor Events

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States